--- title: "Idexx Laboratories: Competitors" description: "Idexx Laboratories compared with companies that share its SEC industry classification: revenue, growth and margins from SEC filings, and how peers are chosen." canonical: https://www.getswoopr.com/stocks/companies/idexx-laboratories/competitors/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Idexx Laboratories: Competitors & Industry Structure ## Direct Answer SEC EDGAR classifies Idexx Laboratories under SIC code 2835 (In Vitro & In Vivo Diagnostic Substances). Among Swoopr's S&P 500 Equal Weight companies, 9 others share that classification; by latest reported revenue, Idexx Laboratories ranks 1 of 10. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes. ## How Does Idexx Laboratories Compare With Its Peers? | Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin | | --- | --- | --- | --- | --- | | **Idexx Laboratories (IDXX)** | $4.3 billion FY2025 | 10.4% | 31.6% | 24.6% | | [Lantheus Holdings Inc. (LNTH)](https://www.getswoopr.com/stocks/companies/lantheus-holdings-inc/) | $1.5 billion FY2025 | 0.5% | 20.2% | 15.2% | | [Myriad Genetics Inc. (MYGN)](https://www.getswoopr.com/stocks/companies/myriad-genetics-inc/) | $825 million FY2025 | -1.6% | -47.0% | -44.4% | | [Intellia Therapeutics Inc. (NTLA)](https://www.getswoopr.com/stocks/companies/intellia-therapeutics-inc/) | $68 million FY2025 | 16.9% | -651.7% | -609.9% | | [Alpha Teknova Inc. (TKNO)](https://www.getswoopr.com/stocks/companies/alpha-teknova-inc/) | $41 million FY2025 | 7.4% | -41.9% | -42.6% | | [ImmuCell Corporation (ICCC)](https://www.getswoopr.com/stocks/companies/immucell-corporation/) | $28 million FY2025 | 4.3% | 6.0% | -3.8% | | [Biomerica Inc. (BMRA)](https://www.getswoopr.com/stocks/companies/biomerica-inc/) | $4 million FY2026 | -16.2% | -119.5% | -84.8% | | [Insight Molecular Diagnostics Inc. (IMDX)](https://www.getswoopr.com/stocks/companies/insight-molecular-diagnostics-inc/) | $4 million FY2025 | 115.6% | -1260.8% | -1.2% | | [Celldex Therapeutics Inc. (CLDX)](https://www.getswoopr.com/stocks/companies/celldex-therapeutics-inc/) | $2 million FY2025 | -78.0% | -18599.8% | -16748.0% | | [Cardio Diagnostics Holdings Inc. (CDIO)](https://www.getswoopr.com/stocks/companies/cardio-diagnostics-holdings-inc/) | $14,825 FY2025 | -57.5% | -43737.5% | -43832.5% | Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care. ![Bar chart of operating margin for Idexx Laboratories and 7 peers: Idexx Laboratories (IDXX) 31.6%, Lantheus Holdings Inc. (LNTH) 20.2%, Myriad Genetics Inc. (MYGN) -47.0%, Intellia Therapeutics Inc. (NTLA) -651.7%, Alpha Teknova Inc. (TKNO) -41.9%, ImmuCell Corporation (ICCC) 6.0%, Biomerica Inc. (BMRA) -119.5%, Insight Molecular Diagnostics Inc. (IMDX) -1260.8%.](https://www.getswoopr.com/images/charts/idexx-laboratories-competitors-peer-margins.webp) *Operating margin of Idexx Laboratories against companies sharing its SEC industry classification, from the table above. Select the chart to open it full size.* ## How Does Idexx Laboratories Rank Among All SEC Filers in Its Industry Code? 10 companies with annual reports in Swoopr's SEC dataset share SIC code 2835 (In Vitro & In Vivo Diagnostic Substances), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars. | Measure | Idexx Laboratories | Median of filers | Rank | | --- | --- | --- | --- | | Revenue | $4.3 billion | $34 million | 1 of 10 | | Revenue growth | 10.4% | 2.4% | 3 of 10 | | Operating margin | 31.6% | -83.2% | 1 of 10 | | Net margin | 24.6% | -43.5% | 1 of 10 | A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality. ## Where These Numbers Come From Every figure on this page is a value Idexx Laboratories reported in its own SEC filings, read from the SEC's XBRL data (accession 0000874716-26-000038 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### Who are Idexx Laboratories's competitors? Companies sharing Idexx Laboratories's SEC classification (SIC code 2835 (In Vitro & In Vivo Diagnostic Substances)) include Lantheus Holdings Inc. (LNTH), Myriad Genetics Inc. (MYGN), Intellia Therapeutics Inc. (NTLA), Alpha Teknova Inc. (TKNO), ImmuCell Corporation (ICCC). Its 10-K names the competitors it considers most relevant. ### How does Idexx Laboratories compare with its peers on margins? Idexx Laboratories's fiscal 2025 operating margin was 31.6%, against a peer median of -119.5%. ### How are these peers chosen? By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict. ### How does Idexx Laboratories rank among all companies in its SEC industry? Among 10 SEC filers under SIC code 2835, Idexx Laboratories ranks 1 by latest revenue, and 1 of 10 by operating margin (31.6% against a median of -83.2%). ## References - [SEC EDGAR: IDEXX LABORATORIES INC /DE Form 10-K filed February 20, 2026](https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/idxx-20251231.htm) - [SEC EDGAR: IDEXX LABORATORIES INC /DE annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=874716&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Idexx Laboratories company dossier](https://www.getswoopr.com/stocks/companies/idexx-laboratories/) - [Idexx Laboratories financial metrics](https://www.getswoopr.com/stocks/companies/idexx-laboratories/metrics/) - [Idexx Laboratories financial risk indicators](https://www.getswoopr.com/stocks/companies/idexx-laboratories/risks/) - [Idexx Laboratories peer comparison](https://www.getswoopr.com/stocks/companies/idexx-laboratories/competitors/) - [Idexx Laboratories business model and revenue mix](https://www.getswoopr.com/stocks/companies/idexx-laboratories/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).